Patents by Inventor Tom Kerppola

Tom Kerppola has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND METHODS FOR TREATING ABERRANT ADRENOCORTICAL CELL DISORDERS
    Publication number: 20220160662
    Abstract: Methods and compositions are provided for treatment of disorders associated with aberrant adrenal cortex cell behavior, including (but not limited to) treatment of adrenocortical carcinoma (ACC), Cushing's syndrome and/or pituitary ACTH excess (Cushing's Disease). Such methods involve administration of an effective amount N-(2,6-bis(1-methylethyl)phenyl)-N?-((1-(4-(dimethylamino)phenyl)cyclopentyl)-methyl)urea hydrochloride to the patient.
    Type: Application
    Filed: June 30, 2021
    Publication date: May 26, 2022
    Inventors: Gary Hammer, Tom Kerppola, Raili Kerppola
  • COMPOUNDS AND METHODS FOR TREATING ABERRANT ADRENOCORTICAL CELL DISORDERS
    Publication number: 20180256524
    Abstract: Methods and compositions are provided for treatment of disorders associated with aberrant adrenal cortex cell behavior, including (but not limited to) treatment of adrenocortical carcinoma (ACC), Cushing's syndrome and/or pituitary ACTH excess (Cushing's Disease). Such methods involve administration of an effective amount N-(2,6-bis(1-methylethyl)phenyl)-N?-((1-(4-(dimethylamino)phenyl)cyclopentyl)-methyl)urea hydrochloride to the patient.
    Type: Application
    Filed: December 12, 2017
    Publication date: September 13, 2018
    Inventors: Gary Hammer, Tom Kerppola, Raili Kerppola
  • Compounds and methods for treating aberrant adrenocortical cell disorders
    Patent number: 9877937
    Abstract: Methods and compositions are provided for treatment of disorders associated with aberrant adrenal cortex cell behavior, including (but not limited to) treatment of adrenocortical carcinoma (ACC), Cushing's syndrome and/or pituitary ACTH excess (Cushing's Disease). Such methods involve administration of an effective amount N-(2,6-bis(1-methylethyl)phenyl)-N?-((1-(4-(dimethyl amino)phenyl)cyclopentyl)-methyl)urea hydrochloride to the patient.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: January 30, 2018
    Assignees: The Regents of the Univeristy of Michigan, Millendo Therapeutics, Inc.
    Inventors: Gary Hammer, Tom Kerppola, Raili Kerppola
  • COMPOUNDS AND METHODS FOR TREATING ABERRANT ADRENOCORTICAL CELL DISORDERS
    Publication number: 20160367507
    Abstract: Methods and compositions are provided for treatment of disorders associated with aberrant adrenal cortex cell behavior, including (but not limited to) treatment of adrenocortical carcinoma (ACC), Cushing's syndrome and/or pituitary ACTH excess (Cushing's Disease). Such methods involve administration of an effective amount N-(2,6-bis(1-methylethyl)phenyl)-N?-((1-(4-(dimethyl amino)phenyl)cyclopentyl)-methyl)urea hydrochloride to the patient.
    Type: Application
    Filed: June 1, 2016
    Publication date: December 22, 2016
    Inventors: Gary Hammer, Tom Kerppola, Raili Kerppola
  • Compounds and methods for treating aberrant adrenocortical cell disorders
    Patent number: 9446010
    Abstract: Methods and compositions are provided for treatment of disorders associated with aberrant adrenal cortex cell behavior, including (but not limited to) treatment of adrenocortical carcinoma (ACC), Cushing's syndrome and/or pituitary ACTH excess (Cushing's Disease). Such methods involve administration of an effective amount N-(2,6-bis(1-methylethyl)phenyl)-N?-((1-(4-(dimethylamino)phenyl)cyclopentyl)-methyl)urea hydrochloride to the patient.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: September 20, 2016
    Assignees: The Regents of the University of Michigan, Millendo Therapeutics, Inc.
    Inventors: Gary Hammer, Tom Kerppola, Raili Kerppola
  • COMPOUNDS AND METHODS FOR TREATING ABERRANT ADRENOCORTICAL CELL DISORDERS
    Publication number: 20160008302
    Abstract: Methods and compositions are provided for treatment of disorders associated with aberrant adrenal cortex cell behavior, including (but not limited to) treatment of adrenocortical carcinoma (ACC), Cushing's syndrome and/or pituitary ACTH excess (Cushing's Disease). Such methods involve administration of an effective amount N-(2,6-bis(1-methylethyl)phenyl)-N?-((1-(4-(dimethylamino)phenyl)cyclopentyl)-methyl)urea hydrochloride to the patient.
    Type: Application
    Filed: July 13, 2015
    Publication date: January 14, 2016
    Inventors: Gary Hammer, Tom Kerppola, Raili Kerppola
  • Compounds and methods for treating aberrant adrenocartical cell disorders
    Patent number: 9107883
    Abstract: Methods and compositions are provided for treatment of disorders associated with aberrant adrenal cortex cell behavior, including (but not limited to) treatment of adrenocortical carcinoma (ACC), Cushing's syndrome and/or pituitary ACTH excess (Cushing's Disease). Such methods involve administration of an effective amount N-(2,6-bis(1-methylethyl)phenyl)-N?-((1-(4-(dimethylamino)phenyl)cyclopentyl)-methyl)urea hydrochloride to the patient.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: August 18, 2015
    Assignees: Atterocor, Inc., The Regents of the University of Michigan
    Inventors: Gary Hammer, Tom Kerppola, Raili Kerppola
  • Compounds and Methods for Treating Aberrant Adrenocartical Cell Disorders
    Publication number: 20130267550
    Abstract: Methods and compositions are provided for treatment of disorders associated with aberrant adrenal cortex cell behavior, including (but not limited to) treatment of adrenocortical carcinoma (ACC), Cushing's syndrome and/or pituitary ACTH excess (Cushing's Disease). Such methods involve administration of an effective amount N-(2,6-bis(1-methylethyl)phenyl)-N?-((1-(4-(dimethylamino)phenyl)cyclopentyl)-methyl)urea hydrochloride to the patient.
    Type: Application
    Filed: March 13, 2013
    Publication date: October 10, 2013
    Inventors: Gary Hammer, Tom Kerppola, Raili Kerppola
  • Ubiquitin mediated fluorescence complementation assay
    Patent number: 7588907
    Abstract: The present invention relates to methods and compositions for identifying covalent joining or modification of proteins. In particular, the present invention relates to covalent fluorescence complementation assays for the detection of modified (e.g., ubiquitinated) proteins. The present invention further relates to the use of such fluorescence complementation assays in drug screening and research applications.
    Type: Grant
    Filed: June 2, 2006
    Date of Patent: September 15, 2009
    Assignee: The Regents of the University of Michigan
    Inventor: Tom Kerppola
  • Ubiquitin mediated fluorescence complementation assay
    Publication number: 20070059731
    Abstract: The present invention relates to methods and compositions for identifying covalent joining or modification of proteins. In particular, the present invention relates to covalent fluorescence complementation assays for the detection of modified (e.g., ubiquitinated proteins). The present invention further relates to the use of such fluorescence complementation assays in drug screening and research applications.
    Type: Application
    Filed: June 2, 2006
    Publication date: March 15, 2007
    Applicant: The Regents of the University of Michigan
    Inventor: Tom Kerppola